Efficacy and safety of PEG-Inferon (peginterferon alpha-2b) for the treatment of chronic hepatitis C

Virchow Biotech0 个研究点目标入组 100 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Adult male or female between 18-65 years (both years inclusive).
•2.Patients with chronic hepatitis C infection.
•3.Presence of serum alanine aminotransferase (ALT) levels 1.5 times greater than normal (N <40 IU/litre).
•4.Compensated liver disease at the time of baseline visit as defined by Child-Pugh class A.
•5.Hemoglobin greater than or equal to 9 g/dL (females),greater than or equal to 10 g/dL (males); platelet count greater than or equal to75 Ã? 109/L; neutrophil count greater than or equal to1.5 Ã? 109/L; thyroid stimulating hormone (TSH) within normal limits (0.35 - 5.50 ÂµIU/mL).
•6.Willing to give written informed consent and adhere to study visit schedule.

•1.Any evidence of other liver diseases HAV, HBV, HDV, alpha 2 anti-trypsin deficiency, Wilson?s disease, primary biliary cirrhosis, alcoholic liver disease or autoimmune liver disease, hemochromatosis.
•2.A chronic alcoholic or drug abuse problem or severe psychiatric condition.
•3.Pregnant or intent to be pregnant during the study period or nursing mothers.
•4.Patients with immune suppression associated with organ transplantation especially liver transplantation.
•5.History of hypersensitivity to interferon or its diluents. Significant psychiatric disease especially depression.
•6.Severe cardiovascular disease.
•7.Patients with human immunodeficiency virus (HIV) infection.

发起方

Virchow Biotech